ABUS Arbutus Biopharma Earnings and EPS analysis

Relative Growth: Rel. Growth: 44

Relative Strength: Rel. Strength: 73

Relative Valuation: Rel. Valuation: 93

Relative Profitability: Rel. Profitability: 100

EPS in 2026 (TTM): $0.8

Last Report Period Date: Jun 30, 2026

As of September 2026, ABUS's trailing twelve months (TTM) EPS stands at $0.8, according to the latest financial reports. In 2025, the company recorded an earnings per share (EPS) of -$0.17, which represents an increase compared to its EPS of -$0.38 in 2024. ABUS reported an EPS of -$0.03 for the quarterly report ending on Jun 30, 2026.

ABUS earnings history

Historical annual and quarterly earnings per share (EPS) data for Arbutus Biopharma

EPS (TTM)

$0.8

EPS Growth YoY (Quarterly)

-400%

EPS (Quarterly)

-$0.03

EPS Growth (Quarterly)

-103.4%

For 2025, Arbutus Biopharma's EPS was -$0.17, an increase of 55.3% from -$0.38 in 2024. For the quarter ending Jun 30, 2026, the EPS was -$0.03, showing a 400% decrease from the same quarter last year. The trailing twelve months (TTM) EPS as of June 2026 is $0.8. In 2024, the annual EPS was -$0.38, showing an increase of 13.6% from 2023.

ABUS EPS vs price chart

ABUS EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

-400%

EPS growth YoY

55.3%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

Over the last 12 months, Arbutus Biopharma has registered an EPS growth of -400% (YoY, quarterly).

ABUS Earnings Waterfall

Breakdown of revenue, profit and net income for Arbutus Biopharma

All data is based on quarterly TTM periods, unless otherwise specified.